Endurance Wealth Management’s Beam Therapeutics BEAM Stock Holding History

Endurance Wealth Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$19K	Hold	625	–	–	﹤0.01%	432
2023 Q1	$19K	Hold	625	–	–	﹤0.01%	437
2022 Q4	$24K	Hold	625	–	–	﹤0.01%	396
2022 Q3	$30K	Hold	625	–	–	0.01%	374
2022 Q2	$24K	Sell	625 -100	-14%	-$3.98K	﹤0.01%	394
2022 Q1	$42K	Buy	725 +100	+16%	+$6.56K	0.01%	368
2021 Q4	$49K	Hold	625	–	–	0.01%	353
2021 Q3	$60K	Hold	625	–	–	0.01%	335
2021 Q2	$57K	Hold	625	–	–	0.01%	346
2021 Q1	$50K	Hold	625	–	–	0.01%	360
2020 Q4	$51K	Sell	625 -300	-32%	-$14.8K	0.01%	326
2020 Q3	$22K	Hold	925	–	–	﹤0.01%	377
2020 Q2	$25K	Buy	+925	New	+$19.9K	﹤0.01%	375

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Endurance Wealth Management's BEAM Position: Q2 2023 in Review

Endurance Wealth Management held its Beam Therapeutics (BEAM) position steady in Q2 2023 at 625 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #432.

Endurance Wealth Management first reported a position in BEAM in Q2 2020 and has held it in 13 quarters since. The position peaked at $60K in Q3 2021. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

Endurance Wealth Management held 625 shares of Beam Therapeutics worth $19K as of Q2 2023.
Endurance Wealth Management left its Beam Therapeutics share count unchanged in Q2 2023.
Beam Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #432 holding.
Endurance Wealth Management first reported a position in Beam Therapeutics in Q2 2020 and has held it in 13 quarters since.
Endurance Wealth Management's Beam Therapeutics position peaked at $60K in Q3 2021.
193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.